|
1
|
Kerlikowske K, Molinaro AM, Gauthier ML,
Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart
K, Chew K, et al: Biomarker expression and risk of subsequent
tumors after initial ductal carcinoma in situ diagnosis. J Natl
Cancer Inst. 102:627–637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Price P, Sinnett HD, Gusterson B, Walsh G,
A'Hern RP and McKinna JA: Duct carcinoma in situ: Predictors of
local recurrence and progression in patients treated by surgery
alone. Br J Cancer. 61:869–872. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Welch HG and Black WC: Overdiagnosis in
cancer. J Natl Cancer Inst. 102:605–613. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma XJ, Salunga R, Tuggle JT, Gaudet J,
Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, et
al: Gene expression profiles of human breast cancer progression.
Proc Natl Acad Sci USA. 100:5974–5979. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Castro NP, Osório CA, Torres C, Bastos EP,
Mourão-Neto M, Soares FA, Brentani HP and Carraro DM: Evidence that
molecular changes in cells occur before morphological alterations
during the progression of breast ductal carcinoma. Breast Cancer
Res. 10:R872008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moelans CB, de Weger RA, Monsuur HN, Maes
AH and van Diest PJ: Molecular differences between ductal carcinoma
in situ and adjacent invasive breast carcinoma: A multiplex
ligation-dependent probe amplification study. Anal Cell Pathol
(Amst). 33:165–173. 2010. View Article : Google Scholar
|
|
7
|
Solin LJ, Gray R, Baehner FL, Butler SM,
Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW
Jr, et al: A multigene expression assay to predict local recurrence
risk for ductal carcinoma in situ of the breast. J Natl Cancer
Inst. 105:701–710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Allen M and Jones LJ: Jekyll and Hyde: The
role of the micro-environment on the progression of cancer. J
Pathol. 223:162–176. 2011. View Article : Google Scholar
|
|
9
|
Bissell MJ, Hall HG and Parry G: How does
the extracellular matrix direct gene expression? J Theor Biol.
99:31–68. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aaltomaa S, Lipponen P, Eskelinen M, Kosma
VM, Marin S, Alhava E and Syrjänen K: Lymphocyte infiltrates as a
prognostic variable in female breast cancer. Eur J Cancer.
28A:859–864. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stewart T, Tsai SC, Grayson H, Henderson R
and Opelz G: Incidence of de-novo breast cancer in women
chronically immunosuppressed after organ transplantation. Lancet.
346:796–798. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee AH, Happerfield LC, Bobrow LG and
Millis RR: Angiogenesis and inflammation in ductal carcinoma in
situ of the breast. J Pathol. 181:200–206. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu
L, Grzesik DA, Qian H, Xue XN and Pollard JW: Macrophages regulate
the angiogenic switch in a mouse model of breast cancer. Cancer
Res. 66:11238–11246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee AH, Dublin EA and Bobrow LG:
Angiogenesis and expression of thymidine phosphorylase by
inflammatory and carcinoma cells in ductal carcinoma in situ of the
breast. J Pathol. 187:285–290. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leek RD, Lewis CE, Whitehouse R, Greenall
M, Clarke J and Harris AL: Association of macrophage infiltration
with angiogenesis and prognosis in invasive breast carcinoma.
Cancer Res. 56:4625–4629. 1996.PubMed/NCBI
|
|
16
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar
|
|
17
|
Biswas SK and Mantovani A: Macrophage
plasticity and interaction with lymphocyte subsets: Cancer as a
paradigm. Nat Immunol. 11:889–896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang X: Tumor-associated macrophages as
potential diagnostic and prognostic biomarkers in breast cancer.
Cancer Lett. 332:3–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bögels M, Braster R, Nijland PG, Gül N,
van de Luijtgaarden W, Fijneman RJ, Meijer GA, Jimenez CR, Beelen
RH and van Egmond M: Carcinoma origin dictates differential skewing
of monocyte function. OncoImmunology. 1:798–809. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hagemann T, Lawrence T, McNeish I, Charles
KA, Kulbe H, Thompson RG, Robinson SC and Balkwill FR:
‘Re-educating' tumor-associated macrophages by targeting NF-kappaB.
J Exp Med. 205:1261–1268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Coussens LM and Pollard JW: Leukocytes in
mammary development and cancer. Cold Spring Harb Perspect Biol.
3:32011. View Article : Google Scholar
|
|
22
|
Guy CT, Cardiff RD and Muller WJ:
Induction of mammary tumors by expression of polyomavirus middle T
oncogene: A transgenic mouse model for metastatic disease. Mol Cell
Biol. 12:954–961. 1992.PubMed/NCBI
|
|
23
|
Scholl SM, Pallud C, Beuvon F, Hacene K,
Stanley ER, Rohrschneider L, Tang R, Pouillart P and Lidereau R:
Anticolony-stimulating factor-1 antibody staining in primary breast
adenocarcinomas correlates with marked inflammatory cell
infiltrates and prognosis. J Natl Cancer Inst. 86:120–126. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin EY, Nguyen AV, Russell RG and Pollard
JW: Colony-stimulating factor 1 promotes progression of mammary
tumors to malignancy. J Exp Med. 193:727–740. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
DeNardo DG, Brennan DJ, Rexhepaj E,
Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD,
Junaid SA, et al: Leukocyte complexity predicts breast cancer
survival and functionally regulates response to chemotherapy.
Cancer Discov. 1:54–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soria G and Ben-Baruch A: The inflammatory
chemokines CCL2 and CCL5 in breast cancer. Cancer Lett.
267:271–285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murdoch C, Giannoudis A and Lewis CE:
Mechanisms regulating the recruitment of macrophages into hypoxic
areas of tumors and other ischemic tissues. Blood. 104:2224–2234.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chavey C, Bibeau F, Gourgou-Bourgade S,
Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G:
Oestrogen receptor negative breast cancers exhibit high cytokine
content. Breast Cancer Res. 9:R152007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ueno T, Toi M, Saji H, Muta M, Bando H,
Kuroi K, Koike M, Inadera H and Matsushima K: Significance of
macrophage chemoattractant protein-1 in macrophage recruitment,
angiogenesis, and survival in human breast cancer. Clin Cancer Res.
6:3282–3289. 2000.PubMed/NCBI
|
|
30
|
Goede V, Brogelli L, Ziche M and Augustin
HG: Induction of inflammatory angiogenesis by monocyte
chemoattractant protein-1. Int J Cancer. 82:765–770. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Valković T, Lucin K, Krstulja M,
Dobi-Babić R and Jonjić N: Expression of monocyte chemotactic
protein-1 in human invasive ductal breast cancer. Pathol Res Pract.
194:335–340. 1998. View Article : Google Scholar
|
|
32
|
Dwyer RM, Potter-Beirne SM, Harrington KA,
Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T and Kerin MJ:
Monocyte chemotactic protein-1 secreted by primary breast tumors
stimulates migration of mesenchymal stem cells. Clin Cancer Res.
13:5020–5027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lebrecht A, Grimm C, Lantzsch T, Ludwig E,
Hefler L, Ulbrich E and Koelbl H: Monocyte chemoattractant
protein-1 serum levels in patients with breast cancer. Tumour Biol.
25:14–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lyon DE, McCain NL, Walter J and Schubert
C: Cytokine comparisons between women with breast cancer and women
with a negative breast biopsy. Nurs Res. 57:51–58. 2008. View Article : Google Scholar :
|
|
35
|
Qian BZ, Li J, Zhang H, Kitamura T, Zhang
J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits
inflammatory monocytes to facilitate breast-tumour metastasis.
Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Luboshits G, Shina S, Kaplan O, Engelberg
S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I and Ben-Baruch
A: Elevated expression of the CC chemokine regulated on activation,
normal T cell expressed and secreted (RANTES) in advanced breast
carcinoma. Cancer Res. 59:4681–4687. 1999.PubMed/NCBI
|
|
37
|
Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki
Y and Abe A: Correlation of tissue and plasma RANTES levels with
disease course in patients with breast or cervical cancer. Clin
Cancer Res. 7:285–289. 2001.PubMed/NCBI
|
|
38
|
Yaal-Hahoshen N, Shina S, Leider-Trejo L,
Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I and
Ben-Baruch A: The chemokine CCL5 as a potential prognostic factor
predicting disease progression in stage II breast cancer patients.
Clin Cancer Res. 12:4474–4480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stormes KA, Lemken CA, Lepre JV, Marinucci
MN and Kurt RA: Inhibition of metastasis by inhibition of
tumor-derived CCL5. Breast Cancer Res Treat. 89:209–212. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Robinson SC, Scott KA, Wilson JL, Thompson
RG, Proudfoot AE and Balkwill FR: A chemokine receptor antagonist
inhibits experimental breast tumor growth. Cancer Res.
63:8360–8365. 2003.PubMed/NCBI
|
|
41
|
Velasco-Velázquez M, Jiao X, De La Fuente
M, Pestell TG, Ertel A, Lisanti MP and Pestell RG: CCR5 antagonist
blocks metastasis of basal breast cancer cells. Cancer Res.
72:3839–3850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Karnoub AE, Dash AB, Vo AP, Sullivan A,
Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg
RA: Mesenchymal stem cells within tumour stroma promote breast
cancer metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Biswas SK, Gangi L, Paul S, Schioppa T,
Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F,
et al: A distinct and unique transcriptional program expressed by
tumor-associated macrophages (defective NF-kappaB and enhanced
IRF-3/STAT1 activation). Blood. 107:2112–2122. 2006. View Article : Google Scholar
|
|
44
|
Jubb AM, Soilleux EJ, Turley H, Steers G,
Parker A, Low I, Blades J, Li JL, Allen P, Leek R, et al:
Expression of vascular notch ligand delta-like 4 and inflammatory
markers in breast cancer. Am J Pathol. 176:2019–2028. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tsutsui S, Yasuda K, Suzuki K, Tahara K,
Higashi H and Era S: Macrophage infiltration and its prognostic
implications in breast cancer: The relationship with VEGF
expression and microvessel density. Oncol Rep. 14:425–431.
2005.PubMed/NCBI
|
|
46
|
Mahmoud SM, Lee AH, Paish EC, Macmillan
RD, Ellis IO and Green AR: Tumour-infiltrating macrophages and
clinical outcome in breast cancer. J Clin Pathol. 65:159–163. 2012.
View Article : Google Scholar
|
|
47
|
Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A,
Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al:
Expression of interleukin-1beta in human breast carcinoma. Cancer.
80:421–434. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Slaney CY, Rautela J and Parker BS: The
emerging role of immunosurveillance in dictating metastatic spread
in breast cancer. Cancer Res. 73:5852–5857. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bidwell BN, Slaney CY, Withana NP, Forster
S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, et
al: Silencing of Irf7 pathways in breast cancer cells promotes bone
metastasis through immune escape. Nat Med. 18:1224–1231. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang L, Huang J, Ren X, Gorska AE, Chytil
A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, et al:
Abrogation of TGF beta signaling in mammary carcinomas recruits
Gr-1+CD11b+ myeloid cells that promote
metastasis. Cancer Cell. 13:23–35. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Melani C, Sangaletti S, Barazzetta FM,
Werb Z and Colombo MP: Amino-biphosphonate-mediated MMP-9
inhibition breaks the tumor-bone marrow axis responsible for
myeloid-derived suppressor cell expansion and macrophage
infiltration in tumor stroma. Cancer Res. 67:11438–11446. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang Y, Lv D, Kim HJ, Kurt RA, Bu W, Li Y
and Ma X: A novel role of hematopoietic CCL5 in promoting
triple-negative mammary tumor progression by regulating generation
of myeloid-derived suppressor cells. Cell Res. 23:394–408. 2013.
View Article : Google Scholar :
|
|
53
|
Diaz-Montero CM, Salem ML, Nishimura MI,
Garrett-Mayer E, Cole DJ and Montero AJ: Increased circulating
myeloid-derived suppressor cells correlate with clinical cancer
stage, metastatic tumor burden, and doxorubicin-cyclophosphamide
chemotherapy. Cancer Immunol Immunother. 58:49–59. 2009. View Article : Google Scholar
|
|
54
|
Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu
W, Shen C, Liu J and Ren X: Myeloid-derived suppressor cells
suppress antitumor immune responses through IDO expression and
correlate with lymph node metastasis in patients with breast
cancer. J Immunol. 190:3783–3797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chin Y, Janseens J, Vandepitte J,
Vandenbrande J, Opdebeek L and Raus J: Phenotypic analysis of
tumor-infiltrating lymphocytes from human breast cancer. Anticancer
Res. 12:1463–1466. 1992.PubMed/NCBI
|
|
56
|
Watanabe MA, Oda JM, Amarante MK and Cesar
Voltarelli J: Regulatory T cells and breast cancer: Implications
for immuno-pathogenesis. Cancer Metastasis Rev. 29:569–579. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kohrt HE, Nouri N, Nowels K, Johnson D,
Holmes S and Lee PP: Profile of immune cells in axillary lymph
nodes predicts disease-free survival in breast cancer. PLoS Med.
2:e2842005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fontenot JD, Gavin MA and Rudensky AY:
Foxp3 programs the development and function of
CD4+CD25+ regulatory T cells. Nat Immunol.
4:330–336. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bacchetta R, Passerini L, Gambineri E, Dai
M, Allan SE, Perroni L, Dagna-Bricarelli F, Sartirana C,
Matthes-Martin S, Lawitschka A, et al: Defective regulatory and
effector T cell functions in patients with FOXP3 mutations. J Clin
Invest. 116:1713–1722. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gavin MA, Torgerson TR, Houston E, DeRoos
P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD and
Rudensky AY: Single-cell analysis of normal and FOXP3-mutant human
T cells: FOXP3 expression without regulatory T cell development.
Proc Natl Acad Sci USA. 103:6659–6664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li B, Saouaf SJ, Samanta A, Shen Y,
Hancock WW and Greene MI: Biochemistry and therapeutic implications
of mechanisms involved in FOXP3 activity in immune suppression.
Curr Opin Immunol. 19:583–588. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Gupta S, Joshi K, Wig JD and Arora SK:
Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its
association with clinicopathologic parameters and angiogenesis.
Acta Oncol. 46:792–797. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bates GJ, Fox SB, Han C, Leek RD, Garcia
JF, Harris AL and Banham AH: Quantification of regulatory T cells
enables the identification of high-risk breast cancer patients and
those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liu Y and Zheng P: FOXP3 and breast
cancer: Implications for therapy and diagnosis. Pharmacogenomics.
8:1485–1487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast
cancer. J Clin Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wernicke M: Quantitative morphologic
assessment of immuno-reactivity in regional lymph nodes of patients
with carcinoma of the breast. Surg Gynecol Obstet. 140:919–924.
1975.PubMed/NCBI
|
|
67
|
Urdiales-Viedma M, Nogales-Fernandez F,
Martos-Padilla S and Sanchez-Cantalejo E: Breast tumors:
Immunoglobulins in axillary lymph nodes. Tumori. 72:575–579.
1986.PubMed/NCBI
|
|
68
|
Tan EM and Shi FD: Relative paradigms
between autoantibodies in lupus and autoantibodies in cancer. Clin
Exp Immunol. 134:169–177. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mahmoud SM, Lee AH, Paish EC, Macmillan
RD, Ellis IO and Green AR: The prognostic significance of B
lymphocytes in invasive carcinoma of the breast. Breast Cancer Res
Treat. 132:545–553. 2012. View Article : Google Scholar
|
|
70
|
Schmidt M, Böhm D, von Törne C, Steiner E,
Puhl A, Pilch H, Lehr HA, Hengstler JG, Kölbl H and Gehrmann M: The
humoral immune system has a key prognostic impact in node-negative
breast cancer. Cancer Res. 68:5405–5413. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
DeNardo DG, Barreto JB, Andreu P, Vasquez
L, Tawfik D, Kolhatkar N and Coussens LM: CD4(+) T cells regulate
pulmonary metastasis of mammary carcinomas by enhancing protumor
properties of macrophages. Cancer Cell. 16:91–102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
van der Most RG, Currie AJ, Robinson BW
and Lake RA: Decoding dangerous death: How cytotoxic chemotherapy
invokes inflammation, immunity or nothing at all. Cell Death
Differ. 15:13–20. 2008. View Article : Google Scholar
|
|
73
|
Zitvogel L, Apetoh L, Ghiringhelli F,
André F, Tesniere A and Kroemer G: The anticancer immune response:
Indispensable for therapeutic success? J Clin Invest.
118:1991–2001. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mattarollo SR, Loi S, Duret H, Ma Y,
Zitvogel L and Smyth MJ: Pivotal role of innate and adaptive
immunity in anthracycline chemotherapy of established tumors.
Cancer Res. 71:4809–4820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Criscitiello C and Curigliano G:
Immunotherapeutics for breast cancer. Curr Opin Oncol. 25:602–608.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Musolino A, Naldi N, Bortesi B, Pezzuolo
D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R,
Bisagni G, et al: Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of trastuzumab-based therapy in
patients with HER-2/neu-positive metastatic breast cancer. J Clin
Oncol. 26:1789–1796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Perez EA, Thompson EA, Ballman KV,
Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC,
Tenner KS, Jen J, et al: Genomic analysis reveals that immune
function genes are strongly linked to clinical outcome in the North
Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J
Clin Oncol. 33:701–708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ghebeh H, Barhoush E, Tulbah A, Elkum N,
Al-Tweigeri T and Dermime S: FOXP3+ Tregs and
B7-H1+/PD-1+ T lymphocytes co-infiltrate the
tumor tissues of high-risk breast cancer patients: Implication for
immunotherapy. BMC Cancer. 8:572008. View Article : Google Scholar
|
|
82
|
Muenst S, Soysal SD, Gao F, Obermann EC,
Oertli D and Gillanders WE: The presence of programmed death 1
(PD-1)-positive tumor-infiltrating lymphocytes is associated with
poor prognosis in human breast cancer. Breast Cancer Res Treat.
139:667–676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Powles T, Eder JP, Fine GD, Braiteh FS,
Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et
al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in
metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
meta-static melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Robert C, Thomas L, Bondarenko I, O'Day S,
Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al:
Ipilimumab plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Vonderheide RH, LoRusso PM, Khalil M,
Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J,
Mariani GL, et al: Tremelimumab in combination with exemestane in
patients with advanced breast cancer and treatment-associated
modulation of inducible costimulator expression on patient T cells.
Clin Cancer Res. 16:3485–3494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Stagg J, Loi S, Divisekera U, Ngiow SF,
Duret H, Yagita H, Teng MW and Smyth MJ: Anti-ErbB-2 mAb therapy
requires type I and II interferons and synergizes with anti-PD-1 or
anti-CD137 mAb therapy. Proc Natl Acad Sci USA. 108:7142–7147.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Hünig T: The storm has cleared: Lessons
from the CD28 super-agonist TGN1412 trial. Nat Rev Immunol.
12:317–318. 2012. View Article : Google Scholar
|
